Current Edition

Brainomix in collaboration with UK Government-funded NCIMI

The partnership will evaluate AI-powered technology in lung cancer care.

Brainomix – the AI-powered medtech solutions company – has announced its collaboration with the National Consortium of Intelligent Medical Imaging (NCIMI) and three selected NHS sites on a project to optimise and validate its automated cancer tracking tool, e-ACT.

e-ACT measures the size of lung cancer tumours and detects changes in tumour size, indicating treatment response and disease progression. The collaboration will evaluate how automated assessment using e-ACT compares with the observations of medical specialists.

Preliminary data has shown that e-ACT is at least as good as specialist doctors in measuring the size of lung cancer tumours at a single time point. This project will have NHS sites in Truro, Bath and Leeds, allowing Brainomix to develop e-ACT and demonstrate the potential impact that technology has to improve the care of patients with cancer.

The 12-month study will include CT (CAT) scans and clinical data from 200 patients with confirmed lung cancer on systematic therapy. The study team will then evaluate how automated assessment of disease progression and treatment response using e-ACT compares to radiologist analysis. The research will also include a descriptive analysis of tumour dynamics using e-ACT in a representative NHS cohort.

This new project also builds on a previous successful collaboration between NCIMI and Brainomix in the stroke space.

Dr Michalis Papadakis, chief executive officer and co-founder of Brainomix, explained: “We are excited to embark on this project, and thank NCIMI for their ongoing support. The preliminary results for e-ACT are very promising. With this new collaboration, we have an opportunity to elevate the level of validation and refinement using a broad and robust dataset, which will bring e-ACT closer to a tool which improves clinical decision-making and further personalises care for cancer patients.”

Mark Beggs, chief operating officer at NCIMI, concluded: “We are delighted that this second Brainomix project has started. Both teams have worked effectively to secure ethical approval and to ensure contracts are in place. This study builds on the existing relationships with Royal Cornwall, Leeds and Bath NHS Trusts who have been great contributors to other NCIMI projects.”

“We are especially pleased that Brainomix can build on the success of its e-Stroke product and expand into new therapeutic areas. We are looking forward to seeing early progress with the e-ACT project,” he added.

Lung cancer remains the third most common cancer in the UK and the leading cause of cancer-related death. Despite therapeutic advances over the past few decades, 60% of patients diagnosed with lung cancer die within the first year and only 16% survive the past five years.